New Lung Cancer Drug Works in Trial

Tuesday, 13 Aug 2013 12:06 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014.
Lilly shares were up 4 percent in premarket trading.
The drug, necitumumab or IMC-11F8, was given to patients with advanced non-small cell lung cancer in combination with already-approved chemotherapy drug gemcitabine and cisplatin, and was compared with chemotherapy alone.
"If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer," Richard Gaynor, Lilly's vice president for product development and medical affairs, said in a statement.
The company's stock closed at $54.05 on the New York Stock Exchange on Monday.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Only 28% of ALS Ice Bucket Donations Used For Research

Sunday, 31 Aug 2014 11:17 AM

The ice bucket challenge to raise support for ALS research has gone viral in recent weeks, drawing celebrities, everyd . . .

Clockwork Pacemaker Works Without Batteries

Sunday, 31 Aug 2014 10:26 AM

Swiss engineers have developed a prototype battery-less pacemaker based on a self-winding wristwatch. . . .

New Cholesterol Drug Cuts Heart Risk in Half

Sunday, 31 Aug 2014 10:15 AM

A new cholesterol-lowering drug roughly halved the number of heart attacks and strokes in a clinical trial, researchers  . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved